are compounded semaglutide being discontinued compounded GLP-1 medications may soon be phased out - Why iscompoundedtirzepatide stillbeingsold They didn't discontinue it on their terms Are Compounded Semaglutide Being Discontinued? Navigating the Latest FDA Policies

Compoundedtirzepatide banned The landscape of semaglutide and its compounded forms is undergoing a significant shift, prompting many to ask: are compounded semaglutide being discontinued? The answer, for many patients and healthcare providers, is a complex yes2026年2月4日—FDA has warned companies that have illegally sold unapproved drugs containingsemaglutide, tirzepatide or retatrutide that are falsely labeled “for research .... Recent actions by the U.2025年3月11日—State-licensed pharmacies muststop making most compounded semaglutide (copies of Novo Nordisk's Wegovy and Ozempic) by April 22, and larger ...SNovo Nordisk Urges FDA to Ban Compounded Semaglutide. Food and Drug Administration (FDA) are restricting the production and sale of compounded semaglutide, particularly concerning its use for weight management. This change is largely driven by the resolution of the semaglutide shortage, which has led to new policies for compounding pharmacies.

For a significant period, the semaglutide shortage created a demand for compounded alternatives to popular GLP-1 medications like Ozempic and Wegovy.2026年2月4日—FDA has warned companies that have illegally sold unapproved drugs containingsemaglutide, tirzepatide or retatrutide that are falsely labeled “for research ... These compounding pharmacies stepped in to provide what many perceived as more affordable or accessible versions of semaglutide. However, the FDA's stance has evolved.What Patients Need to Know About the GLP-1 FDA Policy Changes On February 21, 2025, the FDA announced that the semaglutide shortage was officially over. This declaration has had a direct impact on the ability of compounding pharmacies to produce these drugs.Compounders sue FDA again over declaring end ...

Key Dates and Restrictions on Compounded Semaglutide

The FDA's clarification of policies for compounders has introduced several key deadlines. Most notably, the grace periods for compounded semaglutide and tirzepatide injections have ended. As of May 22, 2025, compounding pharmacies are largely no longer allowed to make and sell semaglutide injections.2025年2月28日—The FDA's recent decision to removesemaglutidefrom the drug shortage list marks a significant shift forcompoundingpharmacies. This prohibition extends to compounded versions of Ozempic and other GLP-1 drugs that were made by smaller pharmacies and sold without direct FDA approval. The rationale behind this restriction is rooted in the FDA's concern over unapproved drugs, including those containing semaglutide, tirzepatide, or retatrutide, which have sometimes been falsely labeled for research purposes.FDA Removes Semaglutide from the Drug Shortage List

To be precise, state-licensed pharmacies were required to stop making most compounded semaglutide by April 22, 2025. Larger 503B outsourcing facilities have a slightly later deadline, with compounding of semaglutide continuing until at least May 22, 2025. This phased approach aims to provide a transitional period for the market.2025年3月21日—Masscompoundingof Novo Nordisk'ssemaglutide— the active ingredient in Wegovy and Ozempic — is supposed to stop by the end of May. Zepbound ... The FDA has officially removed semaglutide from its drug shortage list, a move that signifies the end of the justification for widespread compounding of these specific medications.

The Impact on Patients and Alternatives

The phasing out of compounded semaglutide and other compounded GLP-1 medications may pose challenges for some individuals who relied on these options for weight management or diabetes treatment. The expectation is that compounded versions are going away soon2025年8月19日—The FDA ended thesemaglutide shortage on Feb 21, 2025. Learn key deadlines for compounded semaglutide, GLP-1 alternatives and more.. This means that for patients seeking treatment with semaglutide, the primary legitimate route will be through FDA-approved medications2025年2月25日—Last week, FDA announced that there wasno longer a shortage of Novo Nordisk's GLP-1 semaglutide, which is also branded as Ozempic and Wegovy. " .... Novo Nordisk® is the only company in the United States with FDA-approved medicines containing semaglutide, such as Ozempic and Wegovy.

While the trend is towards discontinuation, it's important to understand the nuances. The initial reason for increased compounding was the aforementioned shortage. With the shortage resolved, the FDA's updated policy means that compounded semaglutide is no longer permitted under the previous circumstances2025年4月2日—The FDA's new rule restricting the sale ofcompounded semaglutidecould make it more difficult for some people to obtain affordable weight loss medications.. The drug has been discontinued as a compounded product by many pharmacies due to these regulatory changes, not necessarily on their own terms2025年2月28日—The FDA's recent decision to removesemaglutidefrom the drug shortage list marks a significant shift forcompoundingpharmacies.. For instance, Weight Watchers has adapted to this new reality, and they didn't discontinue it on their terms; rather, the market conditions and regulations prompted the change.

Understanding the FDA's Position

The FDA's actions reflect a commitment to ensuring the safety and efficacy of medications. Their concerns extend to unapproved GLP-1 drugs used for various treatments, including weight loss.2025年2月21日—On February 21, the FDA announced that the shortage ofsemaglutideinjection products has been resolved. This has led to warnings for companies illegally selling unapproved drugs containing semaglutide or tirzepatide. The directive means that compounded versions of these drugs made by smaller pharmacies and sold without FDA approval can no longer be legally produced or soldCompounders sue FDA again over declaring end ....

For patients and healthcare providers, this period of transition requires careful consideration of available and approved treatment optionsNovo Nordisk®is the only company in the United States with FDA-approved medicines containingsemaglutide.Compoundedor knockoffsemaglutidehas not been .... While the era of widespread compounded semaglutide may be drawing to a close, the focus is shifting back to FDA-approved therapies and their established safety profiles. The resolution of the semaglutide and tirzepatide shortages marks a significant turning point, and patients should consult with their healthcare providers to navigate these evolving treatment landscapes and understand what options are best for their individual needs. The question of is compounded semaglutide FDA-approved has a clear answer: no, the compounded versions themselves are not FDA-approved. Only the original formulations from manufacturers like Novo Nordisk carry this designation2025年2月24日—With Novo Nordisk's blockbuster drugs Wegovy and Ozempic back in stock, copycat versions ofsemaglutide are no longer allowed– for now..